Xanthinol nicotinate in peripheral vascular disease

Area of Science:

• Vascular Medicine
• Pharmacology

Background:

• Obliterative vascular disease significantly impacts patient quality of life.
• Limited effective treatment options exist for severe cases, especially when surgery is contraindicated.

Purpose of the Study:

• To evaluate the efficacy and safety of xanthinol nicotinate in patients with severe progressive obliterative vascular disease.

Main Methods:

• A double-blind, placebo-controlled trial was conducted.
• Patients received either xanthinol nicotinate or a placebo.
• Clinical and laboratory findings were assessed during the trial and at follow-up.

Main Results:

• Xanthinol nicotinate significantly improved outcomes in 25 of 33 patients (76%) compared to placebo (4 of 33).
• Follow-up data showed sustained benefits in 14 of 18 patients.
• The drug reduced whole-blood viscosity, cholesterol, and fibrinogen in approximately half of the treated patients.
• Common side effects included prolonged flushing, though many patients tolerated it.

Conclusions:

• Xanthinol nicotinate is a useful therapeutic option for approximately half of patients with severe obliterative vascular disease unsuitable for surgery.
• Caution is advised in patients with coexisting ischemic heart disease.
• Efficacy may be reduced in diabetic patients under 50.